Researchers at Baylor College of Medicine have developed a drug called CS18 that disrupts cancer cells’ ability to survive therapy. The findings, published in Science Advances, support exploring the possibility of using CS18 to treat human cancer in the future.
“Therapeutic resistance is a main obstacle to achieving effective and durable cancer treatments,” said corresponding author Dr. Weei-Chin Lin, professor of medicine—hematology and oncology—and molecular and cellular biology at Baylor. “While some therapies are effective at the beginning, many patients eventually relapse because cancer cells can activate compensatory and convergent biological pathways that allow them to overcome the toxic effects of therapy, promoting survival.”
In the current study, the researchers’ goal was to develop a drug that would target a “biological switchboard”—topoisomerase IIβ-binding protein 1 (TopBP1)—that controls several cancer-driving pathways at once and to determine whether this strategy could deliver durable responses and overcome resistance.









